Business Wire·Jul 23, 2026, 6:00 AM ET

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines

ONC

BeOne Medicies announced a $300 million expansion of its flagship manufacturing facility in Hopewell, New Jersey, bringing total U.S. investment at the site to over $1 billion.
The project adds small molecule manufacturing capacity to the existing biologics production capabilities under one roof at the Princeton West Innovation Campus.
Approximately 120 new full-time jobs will be created, with the Hopewell site headcount expected to reach roughly 240 by the end of 2029.
Construction involves a new three-story, 145,000-square-foot building adjacent to current facilities, bringing the total campus footprint to approximately 545,000 square feet.
The expanded facility is anticipated to be fully operational in 2029 and will include drug product manufacturing, packaging, quality control laboratories, office space, and capacity for future growth.
The investment supports BeOne's pipeline of more than 35 clinical and commercial-stage oncology assets across hematology, solid tumors, breast, lung, liver, gastrointestinal, and other tumor types.
The expansion strengthens BeOne's "global development superhighway," an internal platform combining research, regulatory, manufacturing, and clinical capabilities to reduce development time.
BeOne employs over 2,000 colleagues in the U.S., generated nearly $2 billion in direct U.S. economic impact in 2025, conducted 93 clinical trials in 45 states, delivered therapies to over 2 million patients globally.
The company cites federal tax policies, the Next New Jersey Manufacturing Program, and state leadership as key factors enabling this investment in biopharmaceutical production.